{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:19:03Z","timestamp":1793830743394,"version":"4.6.1"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Steatotic liver disease (SLD) is prevalent among individuals with chronic hepatitis B virus (CHB), yet its impact on clinical outcomes remains controversial.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We used electronic health record data from 98 US healthcare-delivery systems to compare adults with (CHB-SLD) and without SLD (CHB-wo-SLD) from 2000 to 2024. We applied 1: 1 propensity score matching to balance cohorts by demographic and clinical characteristics. We further performed sensitivity analyses in the presence or absence of cirrhosis. We compared incidence rates (IR) and hazard ratios (HRs) of all-cause mortality, hepatocellular carcinoma (HCC), end-stage liver disease (ESLD) events, and detectable HBsAg and HBeAg as markers of seroclearance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 124,932 individuals with CHB (12.43% CHB-SLD), there were 470,707 person-years of observations (median follow-up 2.95 years). Compared with CHB, individuals with CHB-SLD had a lower mortality risk (HR 0.44, 95% CI 0.40-0.48). Fibrosis risk was higher among those with CHB-SLD (vs CHB-wo-SLD) (HR 1.93, 95% CI 1.71-2.19); however, cirrhosis risk was comparable (HR 1.06, 95% CI 0.96-1.18) between cohorts, while HCC risk was lower in the CHB-SLD cohort (HR 0.83, 95% CI 0.70-0.96). The CHB-SLD cohort also had significantly reduced risks of ESLD events, including ascites, spontaneous bacterial peritonitis, variceal bleeding, hepatic encephalopathy, and hepatorenal syndrome (all p &amp;lt; 0.001). Additionally, detectable HBsAg and HBeAg IRs and HRs were lower among CHB-SLD compared to the CHB-wo-SLD cohort: 26.83 vs. 31.96 per 1,000 person-years (HR 0.80, 95% CI 0.73-0.87) and 8.52 vs. 11.36 per 1,000 person-years (HR 0.74, 95% CI 0.65-0.85), respectively. Sensitivity analyses stratified by cirrhosis status supported these findings.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>CHB-SLD status was associated with more favorable outcomes, highlighting the complexity of CHB and SLD interactions.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1566925","type":"journal-article","created":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T07:12:08Z","timestamp":1743577928000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Impact of hepatic steatosis on mortality, hepatocellular carcinoma, end-stage liver disease and HBsAg seroclearance in chronic hepatitis B: a United States cohort study"],"prefix":"10.3389","volume":"16","author":[{"given":"George A.","family":"Yendewa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbinaya","family":"Elangovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Temitope","family":"Olasehinde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Mulindwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mackenzie G.","family":"Cater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Salata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32803","article-title":"Does hepatic steatosis impact chronic hepatitis B","volume":"77","author":"Yip","year":"2023","journal-title":"Hepatology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/liv.14369","article-title":"Chronic hepatitis B and non-alcoholic fatty liver disease: Conspirators or competitors","volume":"40","author":"Zhang","year":"2020","journal-title":"Liver Int"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2011.06801.x","article-title":"Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients","volume":"26","author":"MaChado","year":"2011","journal-title":"J Gastroenterol Hepatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13872","article-title":"Clinical impact of hepatic steatosis on chronic hepatitis B patients in Asia: A systematic review and meta-analysis","volume":"30","author":"Zhou","year":"2023","journal-title":"J Viral Hepat"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.21037\/atm-21-3052","article-title":"Concurrence and impact of hepatic steatosis on chronic hepatitis B patients: a systematic review and meta-analysis","volume":"9","author":"Jiang","year":"2021","journal-title":"Ann Transl Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16595","article-title":"Systematic review with meta-analysis: prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B","volume":"54","author":"Zheng","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0037998","article-title":"Relation of IL28B gene polymorphism with biochemical and histological features in hepatitis C virus-induced liver disease","volume":"7","author":"Ag\u00fandez","year":"2012","journal-title":"PloS One"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s12328-017-0732-5","article-title":"Significance of genetic polymorphisms in patients with nonalcoholic fatty liver disease","volume":"10","author":"Miyaaki","year":"2017","journal-title":"Clin J Gastroenterol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.814209","article-title":"Non-alcoholic fatty liver disease in HIV\/HBV patients - a metabolic imbalance aggravated by antiretroviral therapy and perpetuated by the hepatokine\/adipokine axis breakdown","volume":"13","author":"Iacob","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32792","article-title":"Steatosis, HBV-related HCC, cirrhosis, and HBsAg seroclearance: A systematic review and meta-analysis","volume":"77","author":"Mao","year":"2023","journal-title":"Hepatology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2023.0004","article-title":"Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis","volume":"29","author":"Wong","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1093\/infdis\/jiz058","article-title":"A global meta-analysis of the prevalence of HIV, hepatitis C virus, and hepatitis B virus among people who inject drugs-do gender-based differences vary by country-level indicators","volume":"220","author":"Leung","year":"2019","journal-title":"J Infect Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40249-021-00921-5","article-title":"Treatment outcomes of HIV patients with hepatitis B and C virus co-infections in Southwest China: an observational cohort study","volume":"11","author":"Jia","year":"2022","journal-title":"Infect Dis Poverty"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000000651","article-title":"Prevalence of chronic hepatitis B virus infection in the United States","volume":"115","author":"Lim","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2005.04007.x","article-title":"Hepatic steatosis and the risk of hepatocellular carcinoma in chronic hepatitis C","volume":"20","author":"Kumar","year":"2005","journal-title":"J Gastroenterol Hepatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.965548","article-title":"NAFLD and HBV interplay - related mechanisms underlying liver disease progression","volume":"13","author":"Tourkochristou","year":"2022","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/liv.2013.34.issue-2","article-title":"Toll-like receptors and liver disease","volume":"34","author":"Kesar","year":"2014","journal-title":"Liver Int"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2007.03419.x","article-title":"The role of CD11c(+) hepatic dendritic cells in the induction of innate immune responses","volume":"149","author":"Shu","year":"2007","journal-title":"Clin Exp Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2950","article-title":"Interleukin-21 inhibits HBV replication in vitro","volume":"20","author":"Li","year":"2015","journal-title":"Antivir Ther"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.07.041","article-title":"Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis","volume":"74","author":"Gaul","year":"2021","journal-title":"J Hepatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0607837103","article-title":"PGC-1alpha controls hepatitis B virus through nutritional signals","volume":"103","author":"Shlomai","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.636897","article-title":"Multifaceted interaction between hepatitis B virus infection and lipid metabolism in hepatocytes: A potential target of antiviral therapy for chronic hepatitis B","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Microbiol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-309809","article-title":"HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B","volume":"64","author":"Nassal","year":"2015","journal-title":"Gut"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3366","article-title":"Dynamics of HBV surface antigen related end points in chronic hepatitis B infection: a systematic review and meta-analysis","volume":"25","author":"Chen","year":"2020","journal-title":"Antivir Ther"},{"key":"B27","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1053\/j.gastro.2019.01.019","article-title":"Factors associated with rates of HBsAg seroclearance in adults with chronic HBV infection: A systematic review and meta-analysis","volume":"156","author":"Yeo","year":"2019","journal-title":"Gastroenterology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-009-9140-3","article-title":"HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B","volume":"3","author":"Liaw","year":"2009","journal-title":"Hepatol Int"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15252","article-title":"Impact of NAFLD on the outcome of patients with chronic hepatitis B in Asia","volume":"42","author":"Yang","year":"2022","journal-title":"Liver Int"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.5009\/gnl.2007.1.2.101","article-title":"Molecular pathogenesis of hepatitis-B-virus-associated hepatocellular carcinoma","volume":"1","author":"Park","year":"2007","journal-title":"Gut Liver"},{"key":"B31","doi-asserted-by":"publisher","first-page":"S84","DOI":"10.1016\/j.jhep.2016.02.021","article-title":"Mechanisms of HBV-induced hepatocellular carcinoma","volume":"64","author":"Levrero","year":"2016","journal-title":"J Hepatol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.3390\/jcm10091827","article-title":"Genomics of viral hepatitis-associated liver tumors","volume":"10","author":"P\u00e9neau","year":"2021","journal-title":"J Clin Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"105136","DOI":"10.1016\/j.micpath.2021.105136","article-title":"C-terminal-truncated hepatitis B virus X protein promotes hepatocarcinogenesis by activating the MAPK pathway","volume":"159","author":"Zhang","year":"2021","journal-title":"Microb Pathog"},{"key":"B34","doi-asserted-by":"publisher","first-page":"4964","DOI":"10.3390\/ijms24054964","article-title":"Relevance of HBx for hepatitis B virus-associated pathogenesis","volume":"24","author":"Schollmeier","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B35","doi-asserted-by":"publisher","first-page":"741","DOI":"10.3390\/cells11040741","article-title":"Hepatitis B viral protein HBx and the molecular mechanisms modulating the hallmarks of hepatocellular carcinoma: A comprehensive review","volume":"11","author":"Sivasudhan","year":"2022","journal-title":"Cells"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.virusres.2006.11.007","article-title":"Raf-1 and protein kinase B regulate cell survival through the activation of NF-kappaB in hepatitis B virus X-expressing cells","volume":"125","author":"Um","year":"2007","journal-title":"Virus Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.05.040","article-title":"Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B","volume":"73","author":"Mak","year":"2020","journal-title":"J Hepatol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/liv.2017.37.issue-4","article-title":"The prevalence of steatohepatitis in chronic hepatitis B patients and its impact on disease severity and treatment response","volume":"37","author":"Charatcharoenwitthaya","year":"2017","journal-title":"Liver Int"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30857","article-title":"Nonalcoholic steatohepatitis is associated with liver-related outcomes and all-cause mortality in chronic hepatitis B","volume":"71","author":"Choi","year":"2020","journal-title":"Hepatology"},{"key":"B40","doi-asserted-by":"publisher","first-page":"101155","DOI":"10.1016\/j.aohep.2023.101155","article-title":"NAFLD is associated with less severe liver fibrosis in chronic hepatitis B: A multi-center, retrospective study","volume":"29","author":"Yao","year":"2024","journal-title":"Ann Hepatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1566925\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T13:28:20Z","timestamp":1743773300000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1566925\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,2]]},"references-count":40,"alternative-id":["10.3389\/fimmu.2025.1566925"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1566925","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,2]]},"article-number":"1566925"}}